Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Inhibikase Therapeutics (IKT) Other Gross PP&E Adjustments (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Other Gross PP&E Adjustments for 6 consecutive years, with $117224.0 as the latest value for Q3 2025.

  • Quarterly Other Gross PP&E Adjustments rose 500.36% to $117224.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$237293.0 through Dec 2025, up 93.72% year-over-year, with the annual reading at -$3.8 million for FY2024, 37.47% down from the prior year.
  • Other Gross PP&E Adjustments for Q3 2025 was $117224.0 at Inhibikase Therapeutics, up from $82306.0 in the prior quarter.
  • The five-year high for Other Gross PP&E Adjustments was $117224.0 in Q3 2025, with the low at -$3.8 million in Q4 2024.
  • Average Other Gross PP&E Adjustments over 5 years is -$744502.8, with a median of -$86218.5 recorded in 2021.
  • The sharpest move saw Other Gross PP&E Adjustments plummeted 205.82% in 2024, then soared 500.36% in 2025.
  • Over 5 years, Other Gross PP&E Adjustments stood at -$2.3 million in 2021, then decreased by 11.14% to -$2.5 million in 2022, then fell by 8.78% to -$2.7 million in 2023, then tumbled by 37.47% to -$3.8 million in 2024, then soared by 103.1% to $117224.0 in 2025.
  • According to Business Quant data, Other Gross PP&E Adjustments over the past three periods came in at $117224.0, $82306.0, and $48505.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.